Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMNN
IMNN logo

IMNN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.100
1 Day change
52 Week Range
41.220
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Imunon Inc (IMNN) is not a strong buy at the moment given the lack of positive catalysts, weak financial performance, and no significant trading signals. For a beginner investor with a long-term horizon, this stock does not align with a solid investment strategy currently.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 56.078, and moving averages are converging, indicating no clear trend. Support levels are at 2.911, and resistance is at 3.209. The stock has a 60% chance of declining in the short term.

Positive Catalysts

  • NULL identified. No recent news or significant trading activity from hedge funds or insiders.

Neutral/Negative Catalysts

  • The stock price has declined by 1.59% during regular trading and an additional 2.90% post-market. Financial performance shows declining EPS (-44.51% YoY) and negative net income. Stock trend analysis predicts further declines in the short term.

Financial Performance

In Q4 2025, revenue remained at 0 with no growth, net income improved slightly but remains negative at -$4.22M, and EPS dropped significantly by 44.51% YoY to -2.02. Gross margin remains at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for review.

Wall Street analysts forecast IMNN stock price to rise
1 Analyst Rating
Wall Street analysts forecast IMNN stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.100
sliders
Low
12
Averages
12
High
12
Current: 3.100
sliders
Low
12
Averages
12
High
12
Maxim
Buy
initiated
$10
AI Analysis
2026-04-17
New
Reason
Maxim
Price Target
$10
AI Analysis
2026-04-17
New
initiated
Buy
Reason
Maxim initiated coverage of Imunon with a Buy rating and $10 price target.
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
2025-05-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
2025-05-19
downgrade
Buy
to
Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IMNN
Unlock Now

People Also Watch